Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes current knowledge on the diagnosis and treatment of hirsutism but provides no new clinical results.

This case series observed the efficacy of GnRH analogues in diagnosing and treating various forms of ovarian hyperandrogenism, illustrating their role in symptom management without surgery, particularly for benign conditions and refractory androgen excess.

In this case report, two adolescents developed androgenetic alopecia after treatment with anastrozole for idiopathic short stature, suggesting this potential side effect should be considered in pediatric patients using aromatase inhibitors.

This case report details a postmenopausal woman with hyperandrogenism due to both adrenal adenoma and ovarian hyperthecosis, highlighting the effectiveness of hormonal suppression and venous sampling for diagnosis.

This pharmacovigilance study identified 19 drugs with high potential risk for causing male infertility, including hormonal agents, antineoplastic drugs, and antidepressants, emphasizing the need for fertility counseling and possible sperm cryopreservation in reproductive-age males before using such treatments.

This study found that women treated with GnRHa for central precocious puberty had a higher prevalence of polycystic ovary syndrome in adulthood compared to those with isolated premature thelarche.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

This review discusses female hyperandrogenism, detailing diagnostic criteria and treatment options without reporting new study results; it emphasizes improving health and quality of life for affected women.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This study found that local therapy with trichoriboside and trichosaccharide significantly increased cAMP levels in hair follicles of men with androgenic alopecia, with trichoriboside showing greater activity.

This study found that nanoparticulate trigonelline formulations significantly improved hair length and density in rats with induced alopecia compared to controls and commercial hair oil, though it was not more effective than minoxidil after 30 days.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

This case report describes a post-menopausal woman with severe hirsutism whose high testosterone levels decreased after gonadotropin suppression, indicating residual hormone-producing tissue responsive to gonadotropins.

This review discusses the use of Serenoa repens for benign prostatic hyperplasia symptoms, noting similar efficacy to other treatments but highlights the need for further rigorous trials to confirm effectiveness.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

This study reports that subcutaneous testosterone pellets in peri- and postmenopausal women provided sustained hormone release and potential benefits for sexual function, but raised concerns about safety, variability, and dosing inconsistencies.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This source describes the first successful use of a deslorelin acetate implant to treat alopecia X in a neutered female dog, achieving profuse hair regrowth in 9 months, suggesting an uncomplicated and cost-effective alternative after melatonin failure.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.